Valuation: Integrity Applications, Inc.

Market Cap 4.88M 4.24M 3.95M 3.63M 6.85M 466M 6.96M 46.56M 18.28M 232M 18.34M 17.93M 778M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value 945K 822K 765K 702K 1.33M 90.23M 1.35M 9.02M 3.54M 44.92M 3.55M 3.47M 151M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
84.22%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 55 2026-07-13
Director of Finance/CFO 66 2025-01-27
Chief Operating Officer - 2025-01-31
Director TitleAgeSince
Director/Board Member 59 2024-08-26
Director/Board Member 56 2023-08-24
Chairman 64 2024-02-12
Change 5-day change 1-year change 3-year change Capi.($)
+15.79%+10.00% - - 4.88M
-1.40%+2.59%-1.71%+11.28% 49.37B
-1.28%+12.39%+25.81%+4.50% 39.14B
-1.57%+0.01%+407.78%+620.95% 40.85B
-1.91%-3.25%+4.71%+47.19% 35.81B
-1.74%+8.42%+8.85%+48.87% 30.5B
-2.27%-3.60% - - 16.55B
-0.96%-4.90%+33.88%+125.91% 16.14B
-0.29%-0.70%-2.71%-34.53% 12.77B
-0.64%+2.65%+1.25%+8.92% 13.71B
Average +0.40%+5.78%+59.73%+104.14% 28.32B
Weighted average by Cap. -1.39%+6.72%+77.86%+130.07%

Financials

2024 2025
Net sales - -
Net income -22.6M -19.64M -18.28M -16.79M -31.7M -2.16B -32.19M -216M -84.59M -1.07B -84.87M -83M -3.6B -19.39M -16.85M -15.69M -14.4M -27.2M -1.85B -27.62M -185M -72.57M -921M -72.81M -71.21M -3.09B
Net Debt -5.35M -4.65M -4.33M -3.97M -7.51M -511M -7.62M -51.03M -20.03M -254M -20.09M -19.65M -853M -3.94M -3.42M -3.19M -2.92M -5.52M -376M -5.61M -37.55M -14.74M -187M -14.79M -14.46M -627M
Logo Integrity Applications, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
-